Generic Name and Formulations:
Alglucosidase alfa 5mg/mL; pwd for IV infusion after reconstitution and dilution; preservative-free.
Sanofi Genzyme Company
Indications for LUMIZYME:
Pompe disease (GAA deficiency).
Adults and Children:
Give by IV infusion over 4 hours. 20mg/kg every 2 weeks. Initial infusion rate: 1mg/kg/hr; may increase by 2mg/kg/hr every 30 minutes, if tolerated, to max 7mg/kg/hr.
Discontinue immediately if severe anaphylactic or allergic reactions develop; have appropriate medical support measures available and during rechallenge. Increased risk of acute cardiorespiratory failure with acute underlying respiratory illness or compromised cardiac function. Cardiac hypertrophy (increased risk of cardiac arrhythmia when given general anesthesia for central venous catheter placement). Infants with cardiac dysfunction may require prolonged observation times. Monitor for development of systemic immune complex-mediated reactions; consider discontinuing if occurs. Monitor for IgG antibody formation every 3 months for 2 years, then annually. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Hydrolytic lysosomal glycogen-specific enzyme.
Hypersensitivity reactions, anaphylaxis, rash, purexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension, pallor, rigors, tremor, vomiting, fatigue, myalgia.
Only available through Lumizyme ACE Program. To enroll call (800) 745-4447.
Single-use vial (50mg)—1, 10
Clinical Pain Advisor Articles
- Cannabis Use High in Migraine
- Sustained-Release Sodium Nitrite for Diabetic Neuropathic Pain Not Associated With Headaches
- Restless Leg Syndrome, Fibromyalgia, and Depression Frequent in Migraine
- Percutaneous Electrolysis May Be Useful Adjunct for Subacromial Pain Syndrome
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use
- Deaths After Nonfatal Opioid Overdose: Causes and Risk Factors
- Targeted Educational Intervention Helped Reduce Opioid Exposure in Adult Inpatients
- Systematic Cross-Checking May Reduce Medical Errors in Emergency Departments
- Corticosteroid Plus Lidocaine Injections Do Not Alleviate Pain in Central Lumbar Spinal Stenosis
- Tofacitinib May Effectively Alleviate Pain in RA, Psoriatic Arthritis, and Ankylosing Spondylitis